16-88803877-G-A
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 2P and 3B. PM2BP4_ModerateBS1_Supporting
The NM_030928.4(CDT1):c.46G>A(p.Gly16Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000176 in 1,475,662 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_030928.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDT1 | NM_030928.4 | c.46G>A | p.Gly16Arg | missense_variant | 1/10 | ENST00000301019.9 | NP_112190.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CDT1 | ENST00000301019.9 | c.46G>A | p.Gly16Arg | missense_variant | 1/10 | 1 | NM_030928.4 | ENSP00000301019 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000997 AC: 15AN: 150520Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000183 AC: 3AN: 163920Hom.: 0 AF XY: 0.0000213 AC XY: 2AN XY: 94006
GnomAD4 exome AF: 0.00000830 AC: 11AN: 1325142Hom.: 0 Cov.: 31 AF XY: 0.00000758 AC XY: 5AN XY: 659754
GnomAD4 genome AF: 0.0000997 AC: 15AN: 150520Hom.: 0 Cov.: 32 AF XY: 0.000123 AC XY: 9AN XY: 73458
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 26, 2022 | The c.46G>A (p.G16R) alteration is located in exon 1 (coding exon 1) of the CDT1 gene. This alteration results from a G to A substitution at nucleotide position 46, causing the glycine (G) at amino acid position 16 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 15, 2022 | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 16 of the CDT1 protein (p.Gly16Arg). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with CDT1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1015874). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The arginine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at